clinical trial · NCT07330778
A Study of CDX-622 in Participants With Mild to Moderate Asthma
Mild to Moderate AsthmaCDX-622
brief summary
This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.
started
Jun 1, 2026
primary completion
Mar 1, 2027
completion
Mar 1, 2027
last updated
Jun 4, 2026
detailed description
CDX-622 is a bispecific antibody that binds to stem cell factor (SCF) and thymic stromal lymphopoietin (TSLP). Eligible participants with mild to moderate asthma will receive a single dose of CDX-622 via IV infusion. Additional follow-up visits will be required through EOS (week 12).
official title
An Open-Label, Single-Dose Study to Assess the Safety, Pharmacodynamics, and Pharmacokinetics of CDX-622 in Adults With Mild to Moderate Asthma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol